Eli Lilly has stopped its Phase III trial of semagacestat, a potential Alzheimer's treatment. Memory and thinking in trial participants receiving treatment declined faster than those receiving placebo, and semagacestat was associated with an increased risk of skin cancer.
Another failure of a treatment targeting beta amyloid is sure to further intensify the controversy about whether that protein causes Alzheimer's.
Comments